Evidence map›Paper›PMID 22999323›Full record

ArticleJournal of electrocardiology

Selection of high-risk patients for device intervention with the new advances in technology.

Arthur J Moss

Abstract read
In one paragraph

Article in Journal of electrocardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Arthur J MossDivision of Cardiology, Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642-0653, USA. heartajm@heart.rochester.edu

Funding

LONG QT SYNDROME--POPULATION, GENETIC, &CARDIAC STUDIESR01HL033843 · NHLBI · UNIVERSITY OF ROCHESTER · PI MOSS, ARTHUR J. · 1985 to 2011
$5.9M
NHLBI NIH HHS R01 HL033843
6 · The paper itself

Abstract

The recent clinical therapeutic studies involving high-risk cardiac patients with genetic or acquired heart disease provide valuable insights into the potential for new advances in the technology for improving risk stratification to identify patients who can benefit from device therapy.

Indexed as

Evidence-Based MedicinePatient SelectionCardiac Resynchronization TherapyGenetic Predisposition to DiseaseHeart DiseasesHumansPrevalencePrognosisRisk AssessmentTreatment Outcome

Identifiers

PMID22999323
PMCPMC3505600

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.